Clinical Trials | September 01, 2022
Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Lutio has the potential to offer significant cost savings when available to UK patients.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
The initiative aims to reach out to more than 20 million people across the country and a number of social media influencers have also pledged to extend their whole-hearted support for the noble cause
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
3D CMOS chip for connecting electroactive tissues and organoids to software
Subscribe To Our Newsletter & Stay Updated
